NO20084008L - HLA-A 3303-restricted WT1 peptide and pharmaceutical composition comprising the same - Google Patents

HLA-A 3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Info

Publication number
NO20084008L
NO20084008L NO20084008A NO20084008A NO20084008L NO 20084008 L NO20084008 L NO 20084008L NO 20084008 A NO20084008 A NO 20084008A NO 20084008 A NO20084008 A NO 20084008A NO 20084008 L NO20084008 L NO 20084008L
Authority
NO
Norway
Prior art keywords
peptide
amino acid
pharmaceutical composition
hla
restricted
Prior art date
Application number
NO20084008A
Other languages
Norwegian (no)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of NO20084008L publication Critical patent/NO20084008L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

Det er beskrevet et peptid som omfatter en aminosyresekvens sammensatt av ni tilstøtende aminosyreresidier utledet fra et WT1 -protein, hvori en aminosyreresidie i posisjon 2 i aminosyresekvensen er utvalgt fra gruppen bestående av Ala, Ile, Leu, Val, Phe, Tyr, Ser og Asp og en aminosyreresidie i posisjon 9 i aminosyresekvensen er Arg; et polynukleotid som koder for peptidet; et farmasøytisk preparat som omfatter peptidet; og andre deler av oppfinnelsen.A peptide is described comprising an amino acid sequence composed of nine adjacent amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 of the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 of the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and other parts of the invention.

NO20084008A 2006-02-22 2008-09-19 HLA-A 3303-restricted WT1 peptide and pharmaceutical composition comprising the same NO20084008L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006045287 2006-02-22
PCT/JP2007/053176 WO2007097358A1 (en) 2006-02-22 2007-02-21 Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
NO20084008L true NO20084008L (en) 2008-11-24

Family

ID=38437397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084008A NO20084008L (en) 2006-02-22 2008-09-19 HLA-A 3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Country Status (23)

Country Link
US (5) US8759483B2 (en)
EP (3) EP2518149B1 (en)
JP (1) JP5393144B2 (en)
KR (1) KR101391561B1 (en)
CN (3) CN102250211A (en)
AU (1) AU2007218649B2 (en)
BR (1) BRPI0708125A2 (en)
CA (4) CA2886552A1 (en)
CY (1) CY1113117T1 (en)
DK (2) DK2518149T3 (en)
ES (3) ES2558330T3 (en)
HK (1) HK1125968A1 (en)
IL (4) IL193026A (en)
MX (1) MX2008010842A (en)
MY (1) MY149527A (en)
NO (1) NO20084008L (en)
PH (1) PH12012502372B1 (en)
PL (1) PL1988163T3 (en)
PT (1) PT1988163E (en)
RU (2) RU2435782C2 (en)
SI (1) SI1988163T1 (en)
WO (1) WO2007097358A1 (en)
ZA (1) ZA200806542B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378264T3 (en) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. HLA-DR binding antigenic peptide derived from WT1
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
JP5393144B2 (en) 2006-02-22 2014-01-22 株式会社癌免疫研究所 HLA-A * 3303 restricted WT1 peptide and pharmaceutical composition comprising the same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
RU2680539C2 (en) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Method for activation of helper t cell and composition for use in the method
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
SG193956A1 (en) * 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EP2757373A4 (en) * 2011-09-14 2015-07-01 Int Inst Cancer Immunology Inc Method for measuring anti-wt1 antibody
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2014042226A1 (en) 2012-09-12 2014-03-20 株式会社癌免疫研究所 Antigen-specific helper t-cell receptor genes
KR102258021B1 (en) 2012-12-13 2021-06-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Wt1 vaccine
TWI646970B (en) 2012-12-17 2019-01-11 大塚製藥股份有限公司 Method for activating helper T cells
PT2945647T (en) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
US20140220058A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
JP6512568B2 (en) 2013-02-05 2019-05-15 日東電工株式会社 WT1 peptide cancer vaccine composition for transdermal administration
KR20140099828A (en) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 Vaccine composition for mucosal administration
RU2014102939A (en) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Vaccine composition for transdermal administration
JP6512567B2 (en) 2013-02-05 2019-05-15 日東電工株式会社 WT1 peptide cancer vaccine composition for transdermal administration
CA2840959A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition
EP3231438B1 (en) 2014-12-11 2020-06-17 International Institute of Cancer Immunology, Inc. Wt1 immunotherapy for intraocular angiogenic disease
CA2974066A1 (en) 2014-12-25 2016-06-30 International Institute Of Cancer Immunology, Inc. Method for modifying t cell population
CA2987247A1 (en) 2015-03-20 2016-09-29 The Trustees Of The University Of Pennsylvania Isg15 and its use as an adjuvant
JP6994201B2 (en) 2016-11-09 2022-02-21 国立大学法人大阪大学 Method of modifying T cell population

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033127T2 (en) * 1989-11-13 1999-10-14 Massachusetts Inst Technology LOCALIZATION AND CHARACTERIZATION OF THE WILMS TUMOR GENE
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6270777B1 (en) 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2349442C (en) * 1998-09-30 2012-12-04 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US6797695B1 (en) * 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
WO2002014361A2 (en) 2000-08-17 2002-02-21 Agensys, Inc. NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
TWI318630B (en) * 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
SI20875A (en) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Crystal form of omeprazole
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
WO2004063217A1 (en) 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Dimerized peptide
WO2004067716A2 (en) * 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US6980709B2 (en) 2003-06-20 2005-12-27 Northrop Grumman Corporation Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers
DE602005020121D1 (en) 2004-03-31 2010-05-06 Int Inst Cancer Immunology Inc CANCERANT PEPTIDES FROM WT1
JP5393144B2 (en) 2006-02-22 2014-01-22 株式会社癌免疫研究所 HLA-A * 3303 restricted WT1 peptide and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
ES2558330T3 (en) 2016-02-03
CN101384716A (en) 2009-03-11
KR101391561B1 (en) 2014-05-02
DK2518149T3 (en) 2016-01-11
IL218172A0 (en) 2012-03-29
IL193026A0 (en) 2009-02-11
CN101384716B (en) 2013-03-13
RU2008137635A (en) 2010-03-27
PL1988163T3 (en) 2012-11-30
CA2886552A1 (en) 2007-08-30
US8968745B2 (en) 2015-03-03
RU2435782C2 (en) 2011-12-10
AU2007218649B2 (en) 2013-01-10
PH12012502372A1 (en) 2016-04-04
RU2011132212A (en) 2013-02-10
HK1125968A1 (en) 2009-08-21
CA2638122A1 (en) 2007-08-30
BRPI0708125A2 (en) 2011-05-17
US20140193443A1 (en) 2014-07-10
EP2385117B1 (en) 2016-07-27
MY149527A (en) 2013-09-13
US8933038B2 (en) 2015-01-13
JPWO2007097358A1 (en) 2009-07-16
US20140199332A1 (en) 2014-07-17
EP2385117A1 (en) 2011-11-09
CN102702319B (en) 2015-01-28
US8945578B2 (en) 2015-02-03
JP5393144B2 (en) 2014-01-22
AU2007218649A1 (en) 2007-08-30
US20100292160A1 (en) 2010-11-18
IL232409A0 (en) 2014-06-30
PH12012502372B1 (en) 2016-04-04
DK1988163T3 (en) 2012-08-20
EP1988163A4 (en) 2010-03-17
CN102250211A (en) 2011-11-23
ES2387685T3 (en) 2012-09-28
EP1988163B1 (en) 2012-06-27
US20120195918A1 (en) 2012-08-02
IL232408A0 (en) 2014-06-30
ES2587980T3 (en) 2016-10-28
KR20080097203A (en) 2008-11-04
ZA200806542B (en) 2009-07-29
SI1988163T1 (en) 2012-09-28
EP1988163A1 (en) 2008-11-05
PT1988163E (en) 2012-08-28
US20140193442A1 (en) 2014-07-10
CY1113117T1 (en) 2016-04-13
CA2886551A1 (en) 2007-08-30
CA2886615A1 (en) 2007-08-30
EP2518149B1 (en) 2015-12-16
MX2008010842A (en) 2008-09-01
US8759483B2 (en) 2014-06-24
CN102702319A (en) 2012-10-03
IL193026A (en) 2015-09-24
US8778350B2 (en) 2014-07-15
WO2007097358A1 (en) 2007-08-30
EP2518149A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
NO20084008L (en) HLA-A 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
UA103154C2 (en) Hla-a*-1101-restricted wt1 peptide and pharmaceutical composition comprising thereof
MXPA06010347A (en) Y2 selective receptor agonists for therapeutic interventions.
CO6241137A2 (en) CXCR4 CYCLE PEPTIDE ANTAGONISTS
MX2009004147A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides.
HK1088840A1 (en) Stable analogs of glp-1 glp-1
BRPI0616824B8 (en) chimeric peptide, its use, pharmaceutical composition comprising it, and kit
WO2005089790A3 (en) Y2/y4 selective receptor agonists for therapeutic interventions
RS52747B (en) Therapeutically activealpha-msh analogues
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
MX2010002001A (en) Cdca1 peptide and pharmaceutical agent comprising the same.
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
NZ594302A (en) Beta-arrestin effectors and compositions and methods of use thereof
EA201792362A8 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELIACIA SPRU
WO2010126156A3 (en) Alkaline protease variants
WO2008113536A8 (en) Neurotrophic peptides
EP1842911A4 (en) Hla-binding peptides, dna fragments encoding the same and recombinant vectors
WO2008081812A1 (en) Anti-tumor peptide and use thereof
WO2004087054A3 (en) Methods for modulating gastric secretion using prokineticin receptor antagonists.
DK1915617T3 (en) Methods and compositions for identifying a peptide having an intermolecular interaction with a target of interest
HK1147210A1 (en) Anti-hypertensive agent
EP3771719A8 (en) A peptide binding to tau-protein
NO20084118L (en) Peptidic growth hormone secretion secretable analogous compounds and preparations thereof
BRPI0715331B8 (en) polypeptide comprising an n-terminal portion and a c-terminal portion, and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application